chr2-165315658-G-A
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BA1BP4
This summary comes from the ClinGen Evidence Repository: The c.1571G>A variant in SCN2A is a missense variant predicted to cause substitution of Arginine by Glutamine at amino acid 524 (p.Arg524Gln). The highest population minor allele frequency in gnomAD v2.1.1 is 0.1504% (30/19942 alleles) in Asian population, which is higher than the ClinGen Epilepsy Sodium Channel VCEP threshold (0.01%) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.192, evidence that does not predict a damaging effect on SCN2A function (BP4). In summary, this variant meets the criteria to be classified as BENIGN for autosomal dominant complex neurodevelopmental disorder based on the ACMG/AMP criteria applied, as specified by the ClinGen Epilepsy Sodium Channel VCEP: BA1 and BP4. (Version 1; approved 6/13/2023) LINK:https://erepo.genome.network/evrepo/ui/classification/CA1939839/MONDO:0100038/068
Frequency
Consequence
NM_001040142.2 missense
Scores
Clinical Significance
Conservation
Publications
- complex neurodevelopmental disorderInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Illumina
- developmental and epileptic encephalopathy, 11Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- intellectual disabilityInheritance: AD Classification: DEFINITIVE Submitted by: G2P
- episodic ataxia, type 9Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- seizures, benign familial infantile, 3Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics
- benign familial infantile epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- benign familial neonatal-infantile seizuresInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Dravet syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- genetic developmental and epileptic encephalopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- infantile spasmsInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- malignant migrating partial seizures of infancyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -9 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SCN2A | ENST00000375437.7 | c.1571G>A | p.Arg524Gln | missense_variant | Exon 11 of 27 | 5 | NM_001040142.2 | ENSP00000364586.2 | ||
| SCN2A | ENST00000631182.3 | c.1571G>A | p.Arg524Gln | missense_variant | Exon 11 of 27 | 5 | NM_001371246.1 | ENSP00000486885.1 | ||
| SCN2A | ENST00000283256.10 | c.1571G>A | p.Arg524Gln | missense_variant | Exon 11 of 27 | 1 | ENSP00000283256.6 | |||
| SCN2A | ENST00000424833.5 | c.*54G>A | downstream_gene_variant | 1 | ENSP00000406454.2 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152168Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.000133 AC: 33AN: 248802 AF XY: 0.0000965 show subpopulations
GnomAD4 exome AF: 0.0000568 AC: 83AN: 1461772Hom.: 0 Cov.: 32 AF XY: 0.0000509 AC XY: 37AN XY: 727172 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152286Hom.: 0 Cov.: 33 AF XY: 0.0000806 AC XY: 6AN XY: 74472 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Benign:2
- -
- -
Seizures, benign familial infantile, 3;C3150987:Developmental and epileptic encephalopathy, 11 Benign:1
- -
Complex neurodevelopmental disorder Benign:1
The c.1571G>A variant in SCN2A is a missense variant predicted to cause substitution of Arginine by Glutamine at amino acid 524 (p.Arg524Gln). The highest population minor allele frequency in gnomAD v2.1.1 is 0.1504% (30/19942 alleles) in Asian population, which is higher than the ClinGen Epilepsy Sodium Channel VCEP threshold (0.01%) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.192, evidence that does not predict a damaging effect on SCN2A function (BP4). In summary, this variant meets the criteria to be classified as BENIGN for autosomal dominant complex neurodevelopmental disorder based on the ACMG/AMP criteria applied, as specified by the ClinGen Epilepsy Sodium Channel VCEP: BA1 and BP4. (Version 1; approved 6/13/2023) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at